Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session

125P - Real-world treatment patterns in stage III NSCLC patients: Interim results of a prospective, multicenter, non-interventional study (MOOREA)


31 Mar 2023


Poster Display session


Ligang Xing


Journal of Thoracic Oncology (2023) 18 (4S): S106-S115.


L. Xing1, J. Yu2, R. Zhao3, W. Yang4, Y. Guo5, J. Li6, C. Xiao7, Y. Ren8, L. Dong9, D. Lv10, L. Zhao11, Y. Lin12, X. Zhang13, L. Chen14, A. Zhang15, Y. Wang16, D. Jiang17, A. Liu18, C. Ma19

Author affiliations

  • 1 Jinan/CN
  • 2 Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan/CN
  • 3 General Hospital of Ningxia Medical University, Yinchuan/CN
  • 4 Shanxi Provincial Cancer Hospital, Taiyuan/CN
  • 5 The First Affiliated Hospital of Sun Yat-sen University, Guangzhou/CN
  • 6 Sichuan Cancer Hospital and Institute, Chengdu/CN
  • 7 HuBei Cancer Hospital, Wuhan/CN
  • 8 Huadong Hospital affiliated to Fudan University, Shanghai/CN
  • 9 The First Hospital of Jilin University, Changchun/CN
  • 10 Taizhou Hospital of Zhejiang Province, Taizhou/CN
  • 11 Tianjin Medical University Cancer Institute & Hospital, Tianjin/CN
  • 12 Cancer Hospital of Shantou University Medical College, Shantou/CN
  • 13 Affiliated Qingdao Central Hospital of Qingdao University, Qingdao/CN
  • 14 Guangxi Medical University Cancer Hospital, Nanning/CN
  • 15 Affiliated Hospital of Hebei University, Baoding/CN
  • 16 West China Hospital Sichuan University, Chengdu/CN
  • 17 The Fourth Hospital of Hebei Medical University, Shijiazhuang/CN
  • 18 The Second Affiliated Hospital of Nanchang University, 330006 - Nanchang/CN
  • 19 The First Hospital of Qiqihar, Qiqihar/CN


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 125P


Stage III non-small cell lung cancer (NSCLC) is highly heterogeneous and often warrants multidisciplinary collaboration. Thus, there is a huge unmet need to understand real-world treatment patterns, and relationship to survival outcomes in stage III NSCLC patients.


MOOREA study is a prospective, non-interventional study to assess the real-world treatment patterns and outcomes of Chinese patients with stage III NSCLC. Treatment naïve stage III NSCLC patients were enrolled and assigned to cohort 1 (unresectable) and cohort 2 (resectable). The primary endpoint is treatment pattern, secondary endpoints are progression-free survival, overall survival, and EGFR/ALK/PD-L1 testing rate. Due to the immaturity of survival endpoints, they will not be reported here.


Between July 2019 and February 2022, 437 eligible patients enrolled from 19 centers in China were included in interim analysis (median age 63 years, 32.3% adenocarcinoma). The testing rates for EGFR, ALK, and PD-L1 were 18.1%, 13.3%, and 10.3%, respectively. In Cohort 1, 41.3% (142/344) patients have received chemoradiotherapy (CRT), including 62.7% (89/142) concurrent CRT (cCRT) and 37.3% (53/142) sequential CRT (sCRT). Of patients after cCRT, 52.8% (47/89) further received consolidation therapy, among which 59.6% (28/47) was immunotherapy. For sCRT patients, 34.0% (18/53) received consolidation therapy, with chemotherapy as the majority (44.4%, 8/18). In Cohort 2, all 93 patients have received surgery and 42.4% (39/92) received neoadjuvant therapy (table).

Table: 125P

Treatment patterns in two cohorts

Cohort 1 (344 pts)
CRT142/344 (41.3)
cCRT89/142 (62.7)
Consolidation therapy47/89 (52.8)
sCRT53/142 (37.3)
Consolidation therapy18/53 (34.0)
Cohort 2 (93 pts)
Neoadjuvant treatment
Yes39/92 (42.4)
No53/92 (57.6)
Missing, n1

Note: data are presented as n/N (%) except specifically notified.


MOOREA study presents the real-world treatment pattern for stage III NSCLC in China, showing that treatment options for this subset are varied in clinical practice due to disease heterogeneity. Further survival correlations with different treatment patterns are ongoing.

Clinical trial identification


Legal entity responsible for the study

The authors.


AstraZeneca China.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.